KROS•benzinga•
Keros Therapeutics Stops PAH Drug Development, Shrinks Workforce By 45%
Summary
Keros ends PAH development of cibotercept after Phase 2 safety issues, including pericardial effusions, and plans to cut 45% of workforce amid review.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 29, 2025 by benzinga